Aristotle University Of Thessaloniki (AUTH)
Study of the effect of empagliflozin on an experimental murine model of metabolic associated fatty liver disease
Abstract
dc:descriptionIntroduction: Nonalcoholic fatty liver disease (NAFLD), recently renamed as metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately one-third of the global population and is particularly prevalent in individuals with type 2 diabetes and obesity. This condition, which ranges from simple steatosis to steatohepatitis, hepatic fibrosis and cirrhosis, poses a significant health challenge due to its potential to progress to severe liver damage. Given the increasing prevalence of NAFLD and the limited available treatment options, there is an urgent need for effective prevention and treatment strategies. Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have emerged as potential therapeutic agents, due to their unique mechanism of action, which lowers blood glucose levels by inhibiting renal glucose reabsorption and promoting weight loss. While some SGLT-2i have shown favorable cardiovascular and renal effects, their specific impact on hepatic steatosis, inflammation, and fibrosis in NAFLD remains largely unclear, necessitating further research to determine their therapeutic efficacy.Aim: Τhe present dissertation aimed to evaluate the potential preventive effects of empagliflozin, a SGLT-2i approved for the treatment of type 2 diabetes mellitus, on both the histological and lipidomic profiles of a mouse model fed a fast food diet (FFD). Methods: A total of 24 C57BL/6J mice of both sexes, aged eight to nine weeks, were randomly divided into three groups: a FFD group (n=8), receiving a high-fat, high-cholesterol, high-fructose diet; an EMPA group (n=8), receiving the same FFD with 10 mg/kg/day empagliflozin; and a chow diet (CD) group (n=8) as control group. Mice were weighed, and blood samples were collected every 4 weeks to measure glucose, alanine aminotransferase, aspartate aminotransferase, triglycerides, and total cholesterol. After 25 weeks, the mice were euthanized, and liver tissues were collected for histological evaluation and lipidomics analysis via ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry in tandem (UPLC-TOF-MS/MS).Results: After 25 weeks, there was no significant difference in body weight between the three groups, whereas liver-to-body weight ratio was greater in the EMPA compared to the CD group (p = 0.002). Hepatic fibrosis was marginally different between the three groups (p = 0.045). Fibrosis stage 1 was present in five mice on FFD (62.5%), in one mouse on EMPA (12.5%), and in one mouse on CD (12.5%). Lipogenic, inflammatory, and fibrogenic genes did not differ between the EMPA and FFD groups. Interestingly, mRNA encoding for SGLT-1 and SGLT-2 was detected in the mouse livers. Following untargeted lipidomics analysis, FFD and EMPA groups displayed similar serum lipid profiles, characterized by elevated levels in the majority of identified lipids, particularly glycerophospholipids, compared to the CD group. Conversely, hepatic lipid profiles varied more significantly between the groups. For example, phosphatidylcholine (PC), phosphatidylinositol (PI), and phosphatidylglycerol demonstrated mixed trends in the FFD and EMPA groups compared to the CD group. FFD appears to have a more substantial impact on lipidomic profiles compared to the preventive empagliflozin effect (CV ANOVA=3.43×10⁻6 FFD vs. CD; 7.67 × 10⁻7 EMPA vs. CD; 2.00 × 10⁻2 EMPA vs. FFD). Interestingly, several glycerophospholipids, including PC 34:1, PC 35:1, PC 36:3, PC 38:4, PI 34:2 and PI 38:3, increased in both serum and hepatic tissues of the FFD and EMPA groups compared to the CD group.Conclusions: Empagliflozin treatment in mice on a FFD did not result in any significant effects on morphological, biochemical, or histological features or on the expression of hepatic genes associated with NAFLD compared to those fed a FFD without empagliflozin. The observed effects on mild hepatic fibrosis warrant validation, possibly via studies of longer duration. Additionally, the EMPA group had largely similar lipidomic profile compared to FFD group. However, both EMPA and FFD groups showed distinct lipidomic profiles compared to the CD group.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Makri, Evangelia
- Μακρή, Ευαγγελία
Subjects
dc:subject × 15- Μεταβολικής αιτιολογίας λιπώδης νόσος του ήπατος
- Αναστολείς του συμμεταφορέα γλυκόζης-νατρίου 2
- Εμπαγλιφλοζίνη
- Δίαιτα τύπου fast food
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Nonalcoholic fatty liver disease (NAFLD)
- Sodium-glucose co-transporter 2 inhibitor
- Empagliflozin
- Fast food diet
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινικό και Αυτόνομο σύστημα
- Basic Medicine
- Medical and Health Sciences
- Endocrine and Autonomic Systems
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59811